William Stevenson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2795100/publications.pdf

Version: 2024-02-01

28 papers

444 citations

933447 10 h-index 713466 21 g-index

28 all docs 28 docs citations

times ranked

28

1022 citing authors

#	Article	IF	Citations
1	A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. Blood, 2016, 127, 2791-2803.	1.4	157
2	Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation. Journal of Antimicrobial Chemotherapy, 2017, 72, 3414-3419.	3.0	43
3	The tumour microenvironment is immunoâ€tolerogenic and a principal determinant of patient outcome in EBVâ€positive diffuse large Bâ€cell lymphoma. European Journal of Haematology, 2019, 103, 200-207.	2.2	42
4	Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Advances, 2018, 2, 1522-1531.	5.2	33
5	Tailored and Integrated Web-Based Tools for Improving Psychosocial Outcomes of Cancer Patients: The DoTTI Development Framework. Journal of Medical Internet Research, 2014, 16, e76.	4.3	25
6	A multi-center randomized controlled trial to reduce unmet needs, depression, and anxiety among hematological cancer patients and their support persons. Journal of Psychosocial Oncology, 2020, 38, 272-292.	1.2	20
7	Protocol of a multi-centre randomised controlled trial of a web-based information intervention with nurse-delivered telephone support for haematological cancer patients and their support persons. BMC Cancer, 2015, 15, 295.	2.6	17
8	Mutation specific immunohistochemistry is highly specific for the presence of calreticulin mutations in myeloproliferative neoplasms. Pathology, 2016, 48, 319-324.	0.6	15
9	An integrated approach to inherited platelet disorders: results from a research collaborative, the Sydney Platelet Group. Pathology, 2020, 52, 243-255.	0.6	15
10	Severe Delayed-Onset Neutropenia Induced by Ocrelizumab. Neurohospitalist, The, 2021, 11, 59-61.	0.8	10
11	Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. EJHaem, 2022, 3, 129-138.	1.0	10
12	Inherited Macrothrombocytopenias. Seminars in Thrombosis and Hemostasis, 2014, 40, 774-784.	2.7	8
13	Lymphoma cellâ€of–origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts. British Journal of Haematology, 2018, 181, 272-275.	2.5	8
14	Unrelated Donor Transplant Recipients Given Thymoglobuline Have Superior GRFS When Compared to Matched Related Donor Recipients Undergoing Transplantation without ATG. Biology of Blood and Marrow Transplantation, 2020, 26, 1868-1875.	2.0	8
15	Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: Preâ€transplant predictors of survival, reactivation, and spontaneous clearance. Transplant Infectious Disease, 2021, 23, e13548.	1.7	7
16	Poor mobilization of autologous CD34 ⁺ peripheral blood stem cells in haematology patients undergoing autologous stem cell transplantation is associated with the presence of variants in genes implicated in clonal haematopoiesis of indeterminant potential. British Journal of Haematology, 2021, 193, 841-844.	2.5	6
17	Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival. Leukemia and Lymphoma, 2020, 61, 831-839.	1.3	5
18	Genetic predisposition in acute leukaemia. International Journal of Laboratory Hematology, 2020, 42, 75-81.	1.3	4

#	Article	IF	Citations
19	Intensive chemotherapy and up-front stem cell transplant for double hit lymphoma. Bone Marrow Transplantation, 2020, 55, 1460-1463.	2.4	3
20	Dynamics of Epstein–Barr virus on postâ€transplant lymphoproliferative disorders after antithymocyte globulinâ€conditioned allogeneic hematopoietic cell transplant. Transplant Infectious Disease, 2021, 23, e13719.	1.7	3
21	SUBA-Itraconazole for Primary Antifungal Prophylaxis After Allogeneic Hematopoietic Cell Transplantation. Open Forum Infectious Diseases, 2021, 8, ofab502.	0.9	2
22	1139. Novel Formulation SUBA-Itraconazole Prophylaxis in Patients With Hematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation: Follow-up Survival Data. Open Forum Infectious Diseases, 2018, 5, S342-S342.	0.9	1
23	Combination of the dual PIM/PI3-kinase inhibitor IBL-202 and venetoclax is effective in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2020, 61, 3165-3176.	1.3	1
24	Progress Findings On a Novel Treatment Strategy Using Prolonged, Low-Dose Cytarabine and Thioguanine in Combination with Peg-Filgrastim for Acute Myeloid Leukaemia in Elderly Patients. Blood, 2012, 120, 3612-3612.	1.4	1
25	Laboratory quality assessment of candidate gene panel testing for acute myeloid leukaemia: a joint ALLG / RCPAQAP initiative. Pathology, 2021, 53, 487-492.	0.6	O
26	Clostridium Difficile Infection in Haematology Patients Significantly Increases Length of Stay; A Case Control Study. Blood, 2015, 126, 2108-2108.	1.4	0
27	Interim Positron Emission Tomography-Computed Tomography (PET-CT) Is Predictive of Post-Therapy Outcome in High Grade Transformation of Low Grade Lymphoproliferative Disorders. Blood, 2015, 126, 5038-5038.	1.4	O

Exposure-adjusted adverse events (AEs) comparing blinatumomab to standard of care (SOC) chemotherapy in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r) Tj ETQq0 0 0.rgBT /Overlock 10 T